Edesa Biotech Székhelye
Mi az Edesa Biotech Székhelye?
A Székhelye az Edesa Biotech, Inc. - Canada
Mi a Székhelye meghatározása?
Helye a cég központja.
Foreign companies can be traded on US stock markets and vice-versa. Obligation of foreign companies traded on US exchanges might slightly differ from obligations of domestic companies.
Mit csinál Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.